BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27941172)

  • 1. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
    Saito R; Araki S; Yamamoto Y; Kusuhara K
    J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
    Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
    Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
    Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
    Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
    Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients.
    Huang M; Que Y; Shen X
    J Diabetes Complications; 2015 Apr; 29(3):422-6. PubMed ID: 25659638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 Diabetes.
    Lee AC; Lam JK; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    PLoS One; 2015; 10(9):e0137330. PubMed ID: 26325204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation.
    Lancefield TF; Patel SK; Freeman M; Velkoska E; Wai B; Srivastava PM; Horrigan M; Farouque O; Burrell LM
    PLoS One; 2016; 11(9):e0161715. PubMed ID: 27627677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma advanced glycation end products (AGEs), receptors for AGEs and their correlation with inflammatory markers in middle school-age children.
    Accacha S; Rosenfeld W; Jacobson A; Michel L; Schnurr FJ; Shelov S; Ten S; Boucher-Berry C; Carey DE; Speiser PW; Lowell B; Conroy R; Klein M; Fennoy I; Rapaport R; Rosenbaum M
    Horm Res Paediatr; 2013; 80(5):318-27. PubMed ID: 24217195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
    Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
    Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
    Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
    Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
    Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
    Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
    PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
    Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
    Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of soluble receptor for AGEs contributes to carbonyl stress in schizophrenia.
    Miyashita M; Watanabe T; Ichikawa T; Toriumi K; Horiuchi Y; Kobori A; Kushima I; Hashimoto R; Fukumoto M; Koike S; Ujike H; Arinami T; Tatebayashi Y; Kasai K; Takeda M; Ozaki N; Okazaki Y; Yoshikawa T; Amano N; Washizuka S; Yamamoto H; Miyata T; Itokawa M; Yamamoto Y; Arai M
    Biochem Biophys Res Commun; 2016 Oct; 479(3):447-452. PubMed ID: 27641663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
    Humpert PM; Djuric Z; Kopf S; Rudofsky G; Morcos M; Nawroth PP; Bierhaus A
    Cardiovasc Diabetol; 2007 Mar; 6():9. PubMed ID: 17343760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor.
    Rzepka R; Dołęgowska B; Sałata D; Rajewska A; Budkowska M; Domański L; Kwiatkowski S; Mikołajek-Bedner W; Torbé A
    BMC Pregnancy Childbirth; 2015 Jun; 15():134. PubMed ID: 26059227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study.
    Heier M; Margeirsdottir HD; Gaarder M; Stensæth KH; Brunborg C; Torjesen PA; Seljeflot I; Hanssen KF; Dahl-Jørgensen K
    Cardiovasc Diabetol; 2015 Sep; 14():126. PubMed ID: 26408307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAGE and AGEs in Mild Cognitive Impairment of Diabetic Patients: A Cross-Sectional Study.
    Wang P; Huang R; Lu S; Xia W; Cai R; Sun H; Wang S
    PLoS One; 2016; 11(1):e0145521. PubMed ID: 26745632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.